探讨肿瘤相关物质(TSGF)、糖类抗原125(CA125)及CEA联合测定在卵巢癌早期诊断中的应用价值。对 85例卵巢癌组、54例良性肿瘤组患者及76名对照组分别检测TSGF、CA125和CEA。结果显示:卵巢癌组与良 性肿瘤组和对照组相比,三项标志物的血清含量有显著性差异(P<0．05)。检测阳性率、敏感性、特异性、准确 度、阳性预测值和阴性预测值六个方面,联合检测均优于单项检测,提示血清TSGF、CA125与CEA联合测定对 卵巢癌的早、中期诊断具有一定应用价值。 To investigate the value of TSGF, CA125 and CEA in the early diagnosis of ovarian cancer. TSGF, CA125 and CEA were detected in 85 patients with ovarian cancer, 54 patients with benign tumor and 76 controls. The results showed that the serum levels of the three markers were significantly different between the ovarian cancer group and the benign tumor group and the control group (P <0.05). The detection of positive rate, sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the six aspects of the joint detection are better than a single test, suggesting that serum TSGF, CA125 and CEA combined determination of ovarian cancer early and intermediate diagnosis has Certain application value.